TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.

["Zhao Y", "Wu X", "Li X", "Jiang LL", "Gui X", "Liu Y", "Sun Y", "Zhu B", "Piña-Crespo JC", "Zhang M", "Zhang N", "Chen X", "Bu G", "An Z", "Huang TY", "Xu H"]
Neuron 2019
Open on PubMed

Mutations in triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to increased Alzheimer's disease (AD) risk. Neurobiological functions of TREM2 and its pathophysiological ligands remain elusive. Here we found that TREM2 directly binds to &#x3b2;-amyloid (A&#x3b2;) oligomers with nanomolar affinity, whereas AD-associated TREM2 mutations reduce A&#x3b2; binding. TREM2 deficiency impairs A&#x3b2; degradation in primary microglial culture and mouse brain. A&#x3b2;-induced microglial depolarization, K<sup>+</sup> inward current induction, cytokine expression and secretion, migration, proliferation, apoptosis, and morphological changes are dependent on TREM2. In addition, TREM2 interaction with its signaling adaptor DAP12 is enhanced by A&#x3b2;, regulating downstream phosphorylation of SYK and GSK3&#x3b2;. Our data demonstrate TREM2 as a microglial A&#x3b2; receptor transducing physiological and AD-related pathological effects associated with A&#x3b2;.